Shanghai Scizeng Medical Technology Co Ltd - a subsidiary of Changchun GeneScience Pharmaceutical Co Ltd (GenSci), RTW Investments, a New York-based global full life-cycle investment firm and Yarrow ...

(Alliance News) - RTW Biotech Opportunities Ltd on Thursday said it participated in the series A funding round of clinical stage biotechnology company Yarrow Bioscience Inc ahead of its Nasdaq listing ...

RTW Biotech Opportunities Ltd ("RTW Bio"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, ...

The announcement follows Yarrow’s December 15 licensing agreement with Shanghai Scizeng Medical Technology, a subsidiary of Changchun GeneScience Pharmaceutical, for global ex-China rights to YB-101.

Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) ...

Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients ...

NEW YORK - VYNE Therapeutics Inc. (NASDAQ:VYNE) and Yarrow Bioscience Inc. announced Wednesday they have entered into a definitive merger agreement for an all-stock transaction, with the combined ...

Shanghai Scizeng Medical Technology Co., LTD, a subsidiary of Changchun GeneScience Pharmaceutical Co., Ltd. (“GenSci”), RTW Investments, LP (“RTW”), and Yarrow Bioscience, Inc. (“Yarrow”) today ...